Ikena Oncology: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Ikena Oncology (NASDAQ:IKNA) reported Q3 earnings, beating estimated earnings by 6.98% with an EPS of $-0.4 versus an estimate of $-0.43. However, revenue was down $5.22 million from the same period last year. Last quarter, the company beat on EPS by $0.03, which was followed by a 5.29% drop in the share price the next day.
November 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ikena Oncology's Q3 earnings beat estimates but saw a decrease in revenue compared to last year. Past performance shows a drop in share price following a beat on EPS.
Ikena Oncology beat earnings estimates, which is generally a positive signal. However, the company's revenue was down compared to the same period last year, which is a negative signal. Additionally, past performance shows that the company's share price dropped the day after beating EPS estimates last quarter, which could indicate a similar trend this time.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100